ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 127 filers reported holding ENANTA PHARMACEUTICALS INC in Q3 2017. The put-call ratio across all filers is 0.30 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2020 | $11,000 | +22.2% | 245 | +31.7% | 0.00% | – |
Q2 2020 | $9,000 | -10.0% | 186 | 0.0% | 0.00% | -100.0% |
Q1 2020 | $10,000 | -88.2% | 186 | -86.5% | 0.00% | -66.7% |
Q4 2019 | $85,000 | +750.0% | 1,380 | +1089.7% | 0.00% | +200.0% |
Q3 2018 | $10,000 | -52.4% | 116 | -34.8% | 0.00% | 0.0% |
Q2 2018 | $21,000 | +133.3% | 178 | +21.9% | 0.00% | 0.0% |
Q4 2017 | $9,000 | -65.4% | 146 | -73.8% | 0.00% | -50.0% |
Q3 2017 | $26,000 | +4.0% | 558 | -20.7% | 0.00% | 0.0% |
Q2 2017 | $25,000 | -70.2% | 704 | -74.3% | 0.00% | -75.0% |
Q1 2017 | $84,000 | -58.2% | 2,735 | -54.4% | 0.01% | -66.7% |
Q4 2016 | $201,000 | -38.5% | 6,002 | -51.1% | 0.02% | -29.4% |
Q3 2016 | $327,000 | +118.0% | 12,280 | +79.9% | 0.03% | +61.9% |
Q2 2016 | $150,000 | +200.0% | 6,825 | +301.5% | 0.02% | +200.0% |
Q1 2016 | $50,000 | -85.0% | 1,700 | -77.0% | 0.01% | -85.1% |
Q2 2015 | $333,000 | +674.4% | 7,400 | +428.6% | 0.05% | +683.3% |
Q1 2015 | $43,000 | -75.8% | 1,400 | -60.0% | 0.01% | -76.9% |
Q4 2014 | $178,000 | +6.6% | 3,500 | -17.1% | 0.03% | +8.3% |
Q3 2014 | $167,000 | – | 4,220 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Krensavage Asset Management, LLC | 862,848 | $42,556,000 | 14.73% |
Fairmount Funds Management LLC | 171,147 | $8,441,000 | 3.56% |
ARMISTICE CAPITAL, LLC | 1,648,000 | $81,279,000 | 1.87% |
FARALLON CAPITAL MANAGEMENT LLC | 1,995,000 | $98,393,000 | 0.49% |
Jackson Creek Investment Advisors LLC | 21,409 | $1,056,000 | 0.37% |
Hennion & Walsh Asset Management, Inc. | 113,940 | $5,620,000 | 0.34% |
Virtus ETF Advisers LLC | 14,721 | $726,000 | 0.31% |
Granahan Investment Management | 193,416 | $9,539,000 | 0.20% |
Yorktown Management & Research Co Inc | 4,500 | $222,000 | 0.18% |
JACOBS LEVY EQUITY MANAGEMENT, INC | 242,257 | $11,948,000 | 0.09% |